{
  "docId": "019de071-eb84-776b-8e7d-ce40a476afec",
  "docSlug": "ee62a94395a2a2b10c5eb93465b3bf02",
  "documentTitle": "Kymera | Investor Day Presentation Deck | 105 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 83,
  "pageCount": 105,
  "prevPage": 82,
  "nextPage": 84,
  "slideType": "segmentation",
  "function": "present_framework",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Uses a Venn diagram to segment potential patient populations for MDM2 degradation therapy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-eb84-776b-8e7d-ce40a476afec/83",
  "deckHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec",
  "deckJsonHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec.json",
  "deckAnchorHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec#slide-83",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Venn diagram showing three categories: p53 WT in >50% of Tumors, MOA-specific Sensitivity, and MDM2 Amplification.",
      "attrs": null,
      "subkind": "venn",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c669e1f2-4176-4c2b-b18c-7eac9260ed68",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.65,
        "y": 0.3
      },
      "kind": "list",
      "text": "MDM2 Amplification: Liposarcoma (87%), Sarcoma (19%), Glioblastoma multiforme (7%), Bladder (3%), Cholangiocarcinoma (3%)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86966cc2-2930-4f8e-8980-9c739ebd4b0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.25,
        "x": 0.1,
        "y": 0.3
      },
      "kind": "list",
      "text": "p53 WT in >50% of Tumors: Mesothelioma, Melanoma, DLBCL, Prostate cancer, Cholangiocarcinoma, Cervical cancer, AML, Renal cell cancer, Uveal melanoma, Thyroid cancer, Liposarcoma, HCC, Breast cancer",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a40ab3e4-6d60-46f5-bac9-f680ceda1b06",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.4,
        "y": 0.3
      },
      "kind": "list",
      "text": "MOA-specific Sensitivity: AML, Uveal Melanoma, Lymphomas, Others will be disclosed in upcoming medical meetings",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7ebdce7-0e23-42e6-baba-fcef80530043",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.8
      },
      "kind": "source-note",
      "text": "TCGA Oliner, et al. 2015; TCGA Donehower, et al. 2020",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "183f20c2-1ea1-4452-a616-de8b3e5bea4c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.15,
        "y": 0.05
      },
      "kind": "title",
      "text": "Focus on Indications Where MDM2 Degradation Leads to Acute Apoptotic Response",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f382b04d-0f5c-48a6-9df6-190d6aa2f471",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Venn diagram",
      "slug": "venn-diagram",
      "agent": null,
      "layer": "slide",
      "matchId": "8c6851e3-38eb-4e56-9348-65e6d4bb98d1",
      "evidence": "diagram/venn: Venn diagram showing three categories: p53 WT in >50% of Tumors, MOA-specific Sensitivity, and MDM2 Amplification.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "venn-diagram",
      "slug": null,
      "matchId": "8dccdc5a-20ad-4f71-a9ba-d819e0ba998a",
      "evidence": "Three overlapping circles used to categorize patient indications.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 84,
      "from": 76,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "baf11c7b-bcf3-45f9-a0f0-de730275483d",
      "evidence": "The deck presents the limitations of current approaches and the benefits of Kymera's MDM2 degrader.",
      "position": 1,
      "objective": "To highlight the potential consequences of not adopting TPD, specifically in the context of MDM2 and p53.",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}